Baxter International announced it has submitted the PrisMax system for 510(k) clearance to the U.S. Food and Drug Administration. Baxter intends to provide demonstrations of the PrisMax system at booth #1719 as well as present data on 15 abstracts on HDx therapy enabled by Theranova and Sharesource remote patient management innovations at the American Society of Nephrology’s: Kidney Week 2018 meeting this week. PrisMax is the company’s most advanced technology for continuous renal replacement therapy, which is performed when a patient experiences acute kidney injury. With input from more than 650 healthcare practitioners around the world, the acute care system was designed to make delivering therapy simpler and more efficient while improving treatment accuracy. Baxter also intends to highlight 13 data presentations on the safety, efficacy and health-related quality of life associated with HDx therapy, and two additional presentations on a reported reduction in hospitalizations and an increase in cost efficiencies for PD therapy associated with the use of remote patient management technology.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.